U.S. IT Stock News

NYSE:LVS
NYSE:LVSHospitality

Las Vegas Sands Credit Upgrade Reshapes Debt Costs And Investor Trade Offs

S&P Global Ratings upgraded Las Vegas Sands (NYSE:LVS) and its Macau unit to BBB from BBB-. The upgrade follows what S&P described as a disciplined financial policy, limited new development plans, and a recovery in Macau operations. Soon after the upgrade, Las Vegas Sands issued US$1b in new senior notes intended to refinance existing debt on improved terms. S&P also pointed to the potential for higher shareholder rewards, including the possibility of further share buybacks. For you as an...
NYSE:SLQT
NYSE:SLQTInsurance

SelectQuote (SLQT) Returns To Quarterly Profit But Volatile EPS Tests Bullish Margin Story

SelectQuote (SLQT) just reported a busy Q2 2026, with total revenue of US$537.1 million and net income of US$51.2 million, which translated to basic EPS of US$0.27. The company’s quarterly revenue had previously stood at US$481.1 million with EPS of US$0.31 in Q2 2025, followed by a mix of losses and profits in subsequent periods, before arriving at the current quarter’s figures. For you as an investor, this latest report highlights a balance between improving profitability on one hand and...
NasdaqGM:WLFC
NasdaqGM:WLFCTrade Distributors

Is It Too Late To Consider Willis Lease Finance (WLFC) After Its Recent Share Price Surge?

If you are wondering whether Willis Lease Finance at around US$229 per share still offers value, you are not alone in asking what the current price really reflects. The stock has recently posted returns of 19.6% over 7 days, 30.2% over 30 days, 70.8% year to date and 72.3% over 1 year, with very large gains over 3 and 5 years. Recent headlines have focused on Willis Lease Finance within the capital goods and aircraft leasing space, highlighting how investors are paying closer attention to...
NasdaqGS:PHAT
NasdaqGS:PHATPharmaceuticals

A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline

Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that includes an operating profitability target beginning in the third quarter. See our latest analysis for Phathom Pharmaceuticals. The stock’s recent 12.62% 1 month share price return, alongside a 7.56% 7 day gain, contrasts with a 19.35% year to date share price decline. At the same time, the 1 year total shareholder return above 400% highlights...
NYSE:FND
NYSE:FNDSpecialty Retail

Is It Time To Reconsider Floor & Decor (FND) After A 30% One Year Share Price Drop

If you are wondering whether Floor & Decor Holdings at around US$51 a share is attractively priced or a potential value trap, the starting point is understanding how the current market price lines up against different measures of value. The stock has recently moved 7.0% over the last week and 3.3% over the last month, while the year to date return sits at a 19.0% decline and the 1 year return at a 30.5% decline, which may catch the eye of investors weighing up risk and recovery...
NYSE:CNS
NYSE:CNSCapital Markets

Is It Too Late To Reassess Cohen & Steers (CNS) After Mixed Valuation Signals?

This article examines whether Cohen & Steers at US$69.54 is offering fair value and breaks down what the current price may be indicating about the stock. The share price is up 0.9% over the last week and 11.0% over the past month. Year to date it is up 9.4%, while the 1 year return stands at a 6.4% decline, set against a 3 year return of 42.2% and a 5 year return of 17.1%. Recent headlines have focused on Cohen & Steers in the context of the wider Capital Markets sector, with attention on...
NYSE:OPY
NYSE:OPYCapital Markets

Is It Too Late To Consider Oppenheimer Holdings (OPY) After A 69% One-Year Rally?

Investors may be wondering whether Oppenheimer Holdings at around US$99 a share still offers value, or if most of the opportunity has already been priced in. The stock has been volatile recently, with an 11.3% pullback over the last 7 days alongside a 9.3% gain over 30 days, and returns of 36.8% year to date and 69.4% over the past year. Recent headlines around capital markets activity and trading conditions have kept investor attention on brokers and financial services stocks, including...
NasdaqGS:WFRD
NasdaqGS:WFRDEnergy Services

Is It Too Late To Consider Weatherford International (WFRD) After Its 152% One Year Surge?

If you are wondering whether Weatherford International at around US$108.61 is still offering value after its run, this breakdown will help you see what the current price really reflects. The stock has seen a 14.0% gain over the last 30 days and a 34.3% return year to date, while the 1 year return sits at 151.7% despite a 1.5% decline over the past week. Recent news around Weatherford International has focused on its position within the broader energy services sector and how investors are...
NasdaqCM:SAFX
NasdaqCM:SAFXOil and Gas

Assessing XCF Global (SAFX) Valuation After Reno Restart, Twain Forbearance Deal And New Business Combination

XCF Global (SAFX) has drawn fresh attention after a series of updates, including a Q1 2026 operational briefing, a business combination agreement, a forbearance deal with lender Twain, and a sector conference appearance. See our latest analysis for XCF Global. Recent updates around the Reno facility restart, the business combination agreement, and the Twain forbearance deal have coincided with a sharp shift in sentiment, with a 90 day share price return of 166.1% but a 3 year total...
NYSE:SPB
NYSE:SPBHousehold Products

Spectrum Brands And Oaktree Deal Refocuses Value On Home And Personal Care

Spectrum Brands Holdings (NYSE:SPB) has entered into a partnership with Oaktree Capital Management focused on its Home and Personal Care business. The transaction brings new investment into the segment and marks another step in Spectrum Brands' plan to separate this business from the rest of the company. The move is intended to reshape how Spectrum Brands allocates resources across its portfolio and could influence how investors view the stock. At a share price of $82.38 and with a return...
NasdaqGM:KALV
NasdaqGM:KALVBiotechs

Chiesi Deal Shapes KalVista Shareholder Outlook And Valuation Potential

Chiesi Farmaceutici S.p.A. has entered into a definitive agreement to acquire KalVista Pharmaceuticals (NasdaqGM:KALV). The deal includes a tender offer followed by a merger process, with completion subject to specified closing conditions. Responsibility for EKTERLY®, a treatment for hereditary angioedema (HAE), is set to move from KalVista to Chiesi once the transaction is finalized. KalVista focuses on treatments for hereditary angioedema, and EKTERLY® is a key product in that portfolio...
NasdaqGS:WING
NasdaqGS:WINGHospitality

Wingstop Sales Slide Puts Gas Price Pressures And Valuation In Focus

Wingstop (NasdaqGS:WING) is reporting a rare quarterly sales decline. Management links the weaker sales to higher gas prices pressuring customer spending. The CEO is signaling that sales could shrink further if current cost pressures persist. Wingstop focuses on quick service chicken wings, an area that often leans on steady takeout and delivery traffic. Recent commentary from the company now centers on softer sales and tighter consumer budgets rather than store expansion or menu...
NasdaqCM:ALMU
NasdaqCM:ALMUSemiconductor

Is Aeluma (ALMU) Quietly Reframing Its Defense Positioning With SPIE-Focused Semiconductor Outreach?

Aeluma, Inc. recently presented its compound semiconductor technologies at the SPIE Defense + Security Conference 2026 at the Gaylord Palms Resort & Convention Center in National Harbor, Maryland, underscoring its engagement with defense and advanced imaging stakeholders. This appearance at a specialized defense and security forum highlights how Aeluma is positioning its scalable optical and sensing solutions directly in front of key government and industry decision-makers. We’ll now examine...
NasdaqGS:FRSH
NasdaqGS:FRSHSoftware

Is It Time To Reassess Freshworks (FRSH) After Its 1 Year Share Price Slide?

If you are wondering whether Freshworks stock is starting to look attractively priced or still has work to do, the recent numbers give you a useful starting point. The share price recently closed at US$9.19, with a 10.9% return over the last 7 days and 10.5% over 30 days, set against a year to date return of a 20.8% decline and a 35.6% decline over the past year. Recent headlines around Freshworks have focused on the stock’s weaker 1 year return of a 35.6% decline and its longer term 3 year...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Is It Too Late To Consider Harrow (HROW) After Its Recent Share Price Surge

Wondering whether Harrow at US$40.50 still offers value, or if most of the opportunity is already priced in? This article is built to help you frame that question clearly. The stock has returned 14.7% over the past 30 days, sits on a 67.9% return over 1 year, but is still down 18.9% year to date. This raises fair questions about both upside potential and risk. Recent coverage has focused on Harrow's position in the pharmaceuticals space and how investors are reacting to its latest...
NYSE:AHRT
NYSE:AHRTREITs

Undervalued Small Caps With Insider Buying To Consider In May 2026

The United States market has seen a robust performance recently, climbing 1.8% in the last week and 30% over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks that are perceived as undervalued and have insider buying can provide unique opportunities for investors seeking potential growth.
NYSE:WMB
NYSE:WMBOil and Gas

3 Stocks Estimated To Be Priced Below Intrinsic Value In May 2026

The United States market has shown robust performance, climbing 1.8% in the last week and achieving a 30% increase over the past year, with earnings expected to grow by 16% annually. In this thriving environment, identifying stocks that are priced below their intrinsic value can offer investors opportunities for potential gains while maintaining a focus on fundamental strengths and growth prospects.